<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>86</patient-age><report-id>US-PFIZER INC-2012302081</report-id><gender>female</gender><reactions><reaction>heart beat was fast</reaction><reaction>TIKOSYN did not work for her</reaction><reaction>high blood pressure</reaction><reaction>sick</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>Tikosyn</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Atrial fibrillation</indication><indication>Heart rate increased</indication></indications><patient-age>86</patient-age><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254117_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151549</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2012302081</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-30</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-23</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2012302081</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>86</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientweight>68.481</patientweight>
			<patientheight>170</patientheight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Heart disorder</patientepisodename>
				<patientmedicalcomment>valve replacement surgery</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>heart beat was fast</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Heartbeats increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Heart rate increased</reactionmeddrapt>
				<reactionstartdateformat>602</reactionstartdateformat>
				<reactionstartdate>2012</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>TIKOSYN did not work for her</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug ineffective</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
				<reactionstartdateformat>602</reactionstartdateformat>
				<reactionstartdate>2012</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>high blood pressure</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Blood pressure high</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypertension</reactionmeddrapt>
				<reactionstartdateformat>602</reactionstartdateformat>
				<reactionstartdate>2012</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>sick</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Sickness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Malaise</reactionmeddrapt>
				<reactionstartdateformat>602</reactionstartdateformat>
				<reactionstartdate>2012</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Tikosyn</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>U121273</drugbatchnumb>
				<drugauthorizationnumb>20-931</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>.25</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>0.25 mg, 2x/day</drugdosagetext>
				<drugdosageform normalized="capsule, hard">Capsule, hard</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Atrial fibrillation</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2012</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-29</drugenddate>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugadditional code="ExpDT=??-JUN-2014"/>
				<activesubstance>
					<activesubstancename>DOFETILIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure high</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure high</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Heartbeats increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Heartbeats increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Sickness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Sickness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Tikosyn</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>V121273</drugbatchnumb>
				<drugauthorizationnumb>20-931</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform normalized="capsule, hard">Capsule, hard</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Heart rate increased</drugindication>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugadditional code="ExpDT=??-JUL-2014"/>
				<activesubstance>
					<activesubstancename>DOFETILIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure high</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure high</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Heartbeats increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Heartbeats increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Sickness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Sickness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Tikosyn</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugbatchnumb>V121273</drugbatchnumb>
				<drugauthorizationnumb>20-931</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<drugdosageform normalized="capsule, hard">Capsule, hard</drugdosageform>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugadditional code="ExpDT=??-JUN-2014"/>
				<activesubstance>
					<activesubstancename>DOFETILIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure high</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Blood pressure high</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Heartbeats increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Heartbeats increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Sickness</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Sickness</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<drugdosagetext>UNK</drugdosagetext>
				<activesubstance>
					<activesubstancename>SPIRONOLACTONE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a contactable consumer. This currently 86-year old, <Semaphore x="2699001" class="Race" value="White" score="1.00" ID="C41261">Caucasian</Semaphore>, female consumer started taking <Semaphore x="503546" class="Medicine - dofetilide - Frequency" value="oral" score="0.49" ID=""><Semaphore x="503532" class="Medicine - dofetilide - Dose" value="0.25mg" score="0.49" ID=""><Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">dofetilide </Semaphore>(<Semaphore x="1275713" class="Medicine - Tikosyn - Dose" value="0.25mg" score="0.74" ID=""><Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">TIKOSYN</Semaphore>) <Semaphore x="2162653472489473" class="Medicine - dofetilide - Dose" value="0.25mg" score="0.49" ID="">0.25mg </Semaphore></Semaphore></Semaphore>
     <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral </Semaphore></Semaphore>capsule two times a day for <Semaphore x="1553174" class="Disease or Finding" value="Atrial Fibrillation by ECG Finding" score="1.00" ID="C111092">atrial fibrillation </Semaphore>in 2012. She was prescribed <Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">dofetilide </Semaphore>while hospitalized for six days as her <Semaphore x="1725087" class="AnatomicStructure" value="Cardiac Valve" score="1.00" ID="C12729">heart </Semaphore>was <Semaphore x="2949378" class="MedDRA LLT" value="Fasting" score="1.00" ID="10068315">faster</Semaphore>. Lot number was U121273 and expiration date was Jun2014. Relevant medical history included unspecified <Semaphore x="1725087" class="AnatomicStructure" value="Cardiac Valve" score="1.00" ID="C12729">heart </Semaphore>problem due to which she had <Semaphore x="1724391" class="Procedure" value="Cardiac Therapeutic Procedure" score="0.58" ID="C80430">valve </Semaphore>replacement <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery</Semaphore>. Relevant concomitant medication included <Semaphore x="1215380" class="Medicine" value="Spironolactone" score="0.49" ID="300679">spironolactone</Semaphore>. She did not take anti arrhythmic medications, gastrointestinal medications or psychiatric medications along with <Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">dofetilide</Semaphore>. In 2012, while on <Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">dofetilide </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy</Semaphore>, she mentioned she <Semaphore x="3094643" class="MedDRA LLT" value="Malaise" score="1.00" ID="10025482">felt <Semaphore x="2520622" class="Disease or Finding" value="Sickness" score="1.00" ID="C107499">sick</Semaphore></Semaphore>, her <Semaphore x="1725087" class="AnatomicStructure" value="Cardiac Valve" score="1.00" ID="C12729">heart </Semaphore>beat was <Semaphore x="2949378" class="MedDRA LLT" value="Fasting" score="1.00" ID="10068315">fast</Semaphore>, "<Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">TIKOSYN </Semaphore>did not work for her", "<Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">TIKOSYN </Semaphore><Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">makes </Semaphore>her <Semaphore x="2010282" class="Disease or Finding" value="Heart Rhythm" score="1.00" ID="C87081">heart rhythm </Semaphore>worst" due to which a <Semaphore x="1723997" class="Disease or Finding" value="Cardiac Paraganglioma" score="1.00" ID="C6410">pacemaker </Semaphore>was put in on an unknown date and she had <Semaphore x="3018504" class="MedDRA LLT" value="Hypertension" score="1.00" ID="10020772">high blood pressure</Semaphore>. On 29Nov2012 she stopped <Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">dofetilide </Semaphore>due to all the above mentioned events. Relevant <Semaphore x="1787567" class="Disease or Finding" value="Clinical Test Result" score="1.00" ID="C77140">lab </Semaphore>data included <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiography </Semaphore>(<Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">ECG</Semaphore>) done on an unknown date <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>of which were unknown. At the time of the report, the clinical <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of all the above mentioned events was unknown.<Semaphore x="3204997" class="MedDRA LLT" value="Product quality issue" score="1.00" ID="10069327">Product complaint </Semaphore><Semaphore x="1995595" class="Procedure" value="Group Therapy" score="1.00" ID="C21042">Group </Semaphore>conclusions were providedNDC# and the <Semaphore x="2394141" class="Occupation" value="Pharmacist" score="1.00" ID="C51840">pharmacy </Semaphore>details were unknown to the consumer.Product <Semaphore x="2520936" class="Disease or Finding" value="Sign or Symptom" score="1.00" ID="C100104">Desc </Semaphore>: <Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">TIKOSYN </Semaphore>CAPSULES 0.25 MG X 60UPC/NDC# : 0069-5810-60Lot Number : V121273.Expiration Date : 7 / 2014.Additional Information: <Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">TIKOSYN </Semaphore>pack size unknown.Conclusions: Lot <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">control </Semaphore>records were reviewed and were found satisfactory no event that could promote the observed defect was reported during the in process verifications during the manufacturing <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">operation</Semaphore>. Lot <Semaphore x="1854022" class="Disease or Finding" value="Discoid Lupus Erythematosus" score="1.00" ID="C26820">release </Semaphore>analytical <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were found satisfactory indicating that capsule lot <Semaphore x="1948844" class="Procedure" value="Fulguration" score="1.00" ID="C15390">met </Semaphore>product specification requirements The last product annual records review was <Semaphore x="1557286" class="AnatomicStructure" value="Auditory Cortex" score="1.00" ID="C52712">audited </Semaphore>and found satisfactory indicating that no complaint due to product failing efficacy (potency) had been confirmed for the manufacturing <Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">operation</Semaphore>. All <Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">Tikosyn </Semaphore><Semaphore x="5479145614082049" class="Medicine - Tikosyn - Dose" value="0.25mg" score="0.74" ID="">0.25mg </Semaphore><Semaphore x="5479205743624193" class="Medicine - Tikosyn - Frequency" value="capsule" score="0.49" ID="">capsule </Semaphore>lots manufactured <Semaphore x="1948844" class="Procedure" value="Fulguration" score="1.00" ID="C15390">meet </Semaphore>strict standards of quality prior to commercial distribution. Lot bulk <Semaphore x="1854022" class="Disease or Finding" value="Discoid Lupus Erythematosus" score="1.00" ID="C26820">release </Semaphore>analytical <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were found satisfactory indicating that lot met product specification requirements. The manufacturing batch record of blend lot 12BTKG017 was reviewed and were found satisfactory. The mentioned blend lot is the source lot of lot 12BTKE023 at the encapsulation stage. A trend had been identified for the product and the manufacturing process requires the implementation of the identified changes efforts to enhance performance of potency and blend uniformity <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results</Semaphore>. The evaluation of the <Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">Tikosyn </Semaphore>manufacturing process and <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controls </Semaphore>was <Semaphore x="1568617" class="Disease or Finding" value="Behavior-Related Disorder" score="1.00" ID="C35470">conducted </Semaphore>and the following actions were induded in the change <Semaphore x="2198849" class="Occupation" value="Management Occupations" score="1.00" ID="C97639">management </Semaphore>system as corrective and preventive actions: The temperature and relative humidity were verified prior to start the manufacturing process using a <Semaphore x="2000891" class="AnatomicStructure" value="Hand" score="1.00" ID="C32712">hand </Semaphore>held hygrometer. A permanent Chart Recorded (ID 03-M THR 04DP02) was installed at the Jet Mill Module used to manufacture the blend to monitor the temperature and relative humidity environmental condition through the manufacturing process. The Chart Recorder was implemented through Change Request No. 50022 (Closed 26-Oct 2011). The temperature and relative humidity at the encapsulation module (Module 6) are monitored using the ASPEN System. <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">Controls </Semaphore>at the QC Laboratory have been implemented. The <Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">Dofetilide </Semaphore>Blend and Capsules samples are stored under <Semaphore x="1854518" class="Disease or Finding" value="Disease Controlled" score="1.00" ID="C82500">controlled </Semaphore>temperature and relative humidity conditions in desiccators until tested. Also the holding times between product sampling and testing have been minimized.. The Stability program for <Semaphore x="1275742" class="Medicine" value="Tikosyn" score="1.00" ID="252126">Tikosyn </Semaphore>Capsules shows that the material continues to exhibit good product stability. The manufacturing batch record of capsule lot 12BTKE023 was reviewed and was found satisfactory. The encapsulation lot <Semaphore x="1854022" class="Disease or Finding" value="Discoid Lupus Erythematosus" score="1.00" ID="C26820">release </Semaphore><Semaphore x="1787567" class="Disease or Finding" value="Clinical Test Result" score="1.00" ID="C77140">testing results </Semaphore>were within specification limits.COMPLAINT <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">INVESTIGATION </Semaphore>RECORD: <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">INVESTIGATION </Semaphore>PLANLot Number: V121273Expiration Date: 06-2014ConclusionRevision of the Packaging records, Equipment/room logbook, Complaint History for the product and lot in question, Retain samples analytical testing <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>demonstrated no evidence of unusual events during the manufacturing or packaging of this product that could be related to this particular complaint.Follow up (14Dec2012): New information reported from a contactable consumer includes: suspect data (additional indication, lot number/expiration date and when <Semaphore x="503561" class="Medicine" value="dofetilide" score="0.99" ID="269814">dofetilide </Semaphore>was prescribed) and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>for a previously reported event (<Semaphore x="1723997" class="Disease or Finding" value="Cardiac Paraganglioma" score="1.00" ID="C6410">pacemaker</Semaphore>).Follow up attempts completed. No further information expected.Follow up (10JAN2013) Follow up attempts completed. No further information expected.Follow up (23Jan2013): This is a follow up spontaneous report from a <Semaphore x="3204997" class="MedDRA LLT" value="Product quality issue" score="1.00" ID="10069327">Product Complaint </Semaphore><Semaphore x="1995595" class="Procedure" value="Group Therapy" score="1.00" ID="C21042">Group</Semaphore>: conclusions provided.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>